GlassScriptPhysician profile
Richard Y Chang
NPI 1285620468
$12,903.01
in general payments reported to CMS, 2019-2025
45 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.54 · 2020: $80.55 · 2021: $2,144 · 2022: $3,849 · 2023: $5,003 · 2024: $1,609 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,281 · Education: $975 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,280.75 |
| Education | $974.57 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,600.03 | 2021-2024 | Calquence, Lynparza, Tagrisso |
| Seagen INC. | $1,313.70 | 2021-2023 | Tukysa, Padcev |
| Incyte Corporation | $1,131.97 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Astellas Pharma US INC | $649.10 | 2021-2024 | |
| Glaxosmithkline, LLC. | $608.83 | 2021-2023 | Zejula, Jemperli |
| Novartis Pharmaceuticals Corporation | $573.44 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $524.19 | 2021-2023 | Opdivo, Opdualag, Reblozyl |
| Amgen INC. | $479.07 | 2020-2024 | Lumakras, Xgeva, Vectibix |
| Beigene USA, INC. | $444.60 | 2021-2023 | Brukinsa |
| Pfizer INC. | $404.41 | 2021-2025 | |
| Genentech USA, INC. | $369.25 | 2022-2025 | Venclexta, Lunsumio, Polivy |
| Lilly USA, LLC | $363.99 | 2021-2024 | Verzenio, Retevmo, Jaypirca |
| Puma Biotechnology, INC. | $317.51 | 2022-2023 | Nerlynx |
| Regeneron Healthcare Solutions, INC. | $316.53 | 2021-2024 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $311.02 | 2021-2023 | Ninlaro |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $280.93 | 2021-2023 | Imbruvica |
| Janssen Biotech, INC. | $270.71 | 2021-2023 | Imbruvica, Darzalex, Tecvayli |
| Gilead Sciences, INC. | $237.07 | 2021-2023 | Trodelvy |
| Abbvie INC. | $232.89 | 2022-2024 | Venclexta |
| Jazz Pharmaceuticals INC. | $228.28 | 2021-2023 | |
| Eisai INC. | $207.69 | 2022-2023 | |
| Genzyme Corporation | $201.45 | 2022-2024 | |
| Celgene Corporation | $191.48 | 2021-2024 | Reblozyl, Pomalyst |
| Tempus Ai, INC | $191.44 | 2024-2025 | Xt Cdx |
| Rigel Pharmaceuticals, INC. | $154.59 | 2021-2023 | Rezlidhia, Tavalisse |
| Daiichi Sankyo INC. | $140.45 | 2022-2025 | Enhertu, Injectafer |
| Sobi, INC | $135.78 | 2023 | |
| Pharmaessentia USA Corporation | $134.30 | 2023 | Besremi |
| Genmab U.S., INC. | $116.06 | 2024 | Epkinly |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Sirtex Medical INC | $99.08 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.38 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.31 | 2021-2023 | Gilotrif |
| Epizyme, INC. | $66.09 | 2021-2022 | |
| Emd Serono, INC. | $54.58 | 2022-2023 | Tepmetko, Bavencio |
| Nestle Healthcare Nutrition INC. | $50.48 | 2021-2022 | |
| Morphosys, US INC. | $39.59 | 2022-2023 | Monjuvi |
| Blueprint Medicines Corporation | $35.60 | 2022-2023 | Ayvakit |
| Array Biopharma INC | $34.50 | 2021-2023 | Mektovi, Lorbrena, Braftovi |
| Adc Therapeutics America, INC. | $29.77 | 2022-2023 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Immunogen, INC. | $16.28 | 2023 | Elahere |
| Ipsen Biopharmaceuticals, INC | $15.36 | 2023 | Onivyde, Somatuline Depot |
| Deciphera Pharmaceuticals INC. | $15.17 | 2023 | Qinlock |
| Cti Biopharma Corp. | $14.14 | 2023 | Vonjo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.